Serina Therapeutics, Inc. — Form 8-K
Filed August 13, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 72/100
What the filing says
Serina completed enrollment and dosing of all 8 patients in Cohort 1 of its Phase 1b SER-252 registrational study ahead of guidance (July 2026 vs. Q3 2026 target), with top-line data targeted for H1 2027. Cash balances increased from $3.1M (Dec 2025) to $23.0M (June 2026) via $31.3M financing proceeds in first half 2026. Q2 2026 operating expenses were $6.8M (+19% vs. Q2 2025), with net loss of $8.9M ($0.55/share). Farrell Simon (Pharm.D.) appointed to Board; manufacturing partnership established with Gannet BioChem.
Why this rating
Clinical milestone achieved ahead of schedule and runway extended materially. $23M cash vs. $21.8M market cap is runway-positive. Risk: high cash burn ($11.3M in 6M), limited to ~2 years.
See more from August 13, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.